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Although chemotherapy in non-resectable non-small cell lung
cancer (NSCLC) leads to a modest survival increase (Souquet
et al, 1993), the effect in this disease is far from satisfactory
(Sørensen et al, 1994). Median survival in patients with advanced
NSCLC receiving chemotherapy varies generally from 5 to 9
months, with less than 5% surviving 5 years (Comis et al, 1995).
More effective chemotherapy is needed and development of new
active regimens is necessary to achieve this goal.
Although chemotherapy in NSCLC is considered to be pallia-
tive, the effects of treatment on patients’ quality of life are unclear.
Statements on palliative effects from treatment often pertain to
physicians’ ratings of performance status (Bakker et al, 1986;
Ganz et al, 1989; Minet et al, 1987), although conclusive data on
quality of life based upon patient self-ratings are sparse (Bartel-
Copel et al, 1997). Nevertheless, several recent publications and
reports on NSCLC have incorporated quality-of-life assessment in
the treatment evaluation (Mastekaasa, 1988; Maasilta et al, 1990;
Sarna, 1990; Kosty et al, 1994; Pujol et al, 1994; Billingham et al,
1997; Helsing et al, 1998), indicating an increasing awareness
of one of the primary therapeutic goals with currently available
regimens, i.e. palliation.
Vindesine is one of the active drugs used in NSCLC treatment
with an accumulated response rate of 18% based on single-agent
treatment of 295 patients included in phase II trials (95% confi-
dence limits 13–22%) (Sørensen et al, 1993). The maximal toler-
ated dose when used as single agent is 4 mg m–2 i.v. weekly for
5–10 weeks followed by biweekly administration, but the
majority of studies have used 3 mg m–2 (Sørensen et al, 1993).
The antineoplastic effect is exerted through binding to tubulin
units, which prevents ordered assembly into microtubules and,
instead, at low concentrations leads to the formation of pseudo-
crystaline structures that do not appear to have any functional
activity. The acute dose-limiting toxicity is myelosuppression,
with a nadir at days 7 or 8 and recovery by days 11–13, while
neurotoxicity is the limiting factor in more prolonged treatment
(Bayssas et al, 1980).
Gemcitabine (2¢,2¢-difluorodeoxycytidine) is a deoxycytidine
analogue with structural and metabolic similarities to cytarabine. In
contrast with cytarabine, gemcitabine has shown activity in a
variety of solid tumours, including NSCLC. Gemcitabine is phos-
phorylated intracellularly, and in this form inhibits DNA synthesis
through inhibition of DNA polymerase (Guchelarr et al, 1996).
Several schedules for administration of gemcitabine have been
explored, and a weekly schedule three times every 4 weeks appears
to be the most favourable (Guchelaar et al, 1996). The side-effects
are schedule dependent, consisting of haematological toxicity,
flu-like syndrome, fever, hypotension and liver toxicity. The flu-
like syndrome is dose limiting with frequent administration, such
as treatment for 5 consecutive days every 3 weeks, whereas
myelosuppression with thrombocytopenia (more important than
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Summary Because both vindesine and gemcitabine are active drugs in advanced non-small-cell lung cancer (NSCLC), with different modes
of action and only partly overlapping toxicity, a phase II study was performed. Gemcitabine 1000 mg m–2 was given on days 1, 8 and 15 every
4 weeks, while vindesine 3 mg m–2 was administered weekly for 7 weeks, then every 2 weeks. A total of 42 patients with nonresectable
NSCLC were included. The median age of patients was 56 years; 57% were men, 52% had adenocarcinoma, 31% squamous cell carcinoma
and 17% had large-cell carcinoma. The performance status ranged from 0 to 2 with 83% in performance status 1. The majority (55%) had
stage IV disease, while 40% had stage III B and 5% stage III A disease. WHO grade 3–4 leucopenia occurred in five patients (12%) and 9%
had grade 4 neutropenia. Thrombocytopenia grade 3–4 was observed in six patients (15%). There were no septic death or bleeding episodes.
One patient had a transient WHO grade 4 increase in bilirubin, and four patients had a decrease in glomerular filtration rate below the normal
limit; one of these patients developed a non-reversible renal insufficiency. Ten patients (24%) complained of dyspnoea of uncertain
mechanism, possibly involving bronchoconstriction. There were one complete and seven partial responses among 40 assessable patients
(20%, 95% confidence limits 9–36%). Median response duration was 31 weeks (range 11–83 weeks) and median survival time 31 weeks
(range 2–171 weeks). The current combination of gemcitabine and vindesine does not appear to be promising for further examination
because of the toxicity and somewhat disappointing activity.
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Copenhagen, Denmarkgranulocytopenia) and liver toxicity are dose limiting when gem-
citabine is administered at longer intervals, such as weekly. Less
common side-effects are skin rash, dyspnoea, oedema and protein-
uria, mild alopecia, nausea and occasional vomiting (Guchelaar et
al, 1996). Gemcitabine has, in five studies, involving a total of 546
patients evaluated three times weekly every 4 weeks, revealed a
20% response rate (95% confidence limits 17–23%; Hansen and
Sørensen, 1997). Doses have ranged from 800 to 2100 mg m–2
weekly.
The documented activity of gemcitabine and vindesine when
used as single agents, together with their different modes of action,
combining a pyrimidine antagonist with a tubulin inhibitor, make a
combination of gemcitabine and vindesine attractive for evalua-
tion in patients with non-respectable NSCLC, with respect to both
antineoplastic effect and impact on quality of life.
PATIENTS AND METHODS
Patients
The study was conducted according to the Declaration of Helsinki,
with the protocol being approved by the local ethics committees.
Patients with non-respectable NSCLC stage III A, III B or IV, aged
18–70 years entered the study after giving written informed
consent. Other criteria for study entry included no prior
chemotherapy, bidimensionally or unidimensionally measurable
disease, World Health Organization (WHO) performance status
0–2, life expectancy 12+ weeks, no radio- or corticosteroid
therapy within the previous 3 weeks, leucocytes ³ 3.0 ´ 109 l–1,
platelets ³ 100 ´ 109 and haemoglobin ³ 6.7 mmol l–1. Exclusion
criteria were active infection, brain metastasis, hypercalcaemia,
second malignancy, creatinine level greater than 0.15 mmol l–1,
serum bilirubin level greater than twice the upper normal limit,
aspartate transaminases > 3 times normal and prothrombin > 1.5
times normal. Also, patients with peripheral neuropathy or signifi-
cant neurological or psychiatric disease were excluded. Bone
metastasis could not be used as the sole indicator lesion.
Pretherapy evaluation included a medical examination, WHO
performance score, complete blood cell count, biochemical
profile, liver function tests, ECG, chest radiographs and urine
analysis. A computerized tomographic scan was performed if
disease was not measurable clinically or on chest radiography.
Renal function was evaluated by chrom-EDTA clearance every 8
weeks (Groth et al, 1981).
Before and after each chemotherapy course, patients’ vital signs
and temperature were recorded. The routine blood tests (complete
blood count, biochemical profile, liver function tests) and urine
analysis were repeated weekly. Chest radiography and other exam-
inations necessary for evaluating response status were performed
every 4 weeks.
Treatment
Gemcitabine 1000 mg m–2 was dissolved in 0.9% saline to a
concentration of 20 mg ml–1 or less and infused over 30 min on
days 1, 8 and 15, with no gemcitabine being administered on day
22. Courses were repeated every 28 days. Vindesine 3 mg m–2
diluted to a concentration of 1 mg m–2 was administered intra-
venously over 10 min weekly for 7 weeks, then every two weeks.
Treatment with gemcitabine and vindesine for 28 days constituted
one treatment course.
Response to therapy
WHO criteria were used in response assessment and evaluation of
toxicity (WHO, 1979). The duration of response was calculated
from the first day of chemotherapy until disease progression or
death.
In unidimensionally measurable lesions, partial remission was
defined as a definite decrease in the size of lesions of at least 50%
as evaluated by two observers and with a duration of at least 4
weeks. Treatment was discontinued in the case of disease progres-
sion or if severe toxicity was observed. Patients with disease
response or stable disease continued therapy until progression.
Dose modifications
The dose of both gemcitabine and vindesine was reduced to 75%
if the white blood cell count was 2.0–2.9 ´ 109 l–1 or the thrombo-
cytes were 50–99 ´ 109 l–1 when chemotherapy was due. Both
gemcitabine and vindesine were omitted if white blood cell count
was less than 2.0 ´ 109 l–1 or the thrombocyte count was less than
50 ´ 109 l–1. Vindesine was reduced by 50% if WHO grade II
peripheral neurotoxicity was encountered and omitted if WHO
grade III or IV toxicity occurred. Patients who experienced other
types of grade III non-haemotological toxicity had both their
gemcitabine and vindesine dose reduced by 50%, and patients
with grade IV non-haematological toxicity were taken off study
unless a response to chemotherapy had occurred. In these latter
cases, a 50% dose reduction could be applied when toxicity
had disappeared at the discretion of the physician in charge of
treatment.
A dose escalation of vindesine and gemcitabine of 20%
was permitted if the previous course was associated with a WHO
toxicity score ≤ 1.
Quality-of-life evaluation
Quality-of-life was assessed by the European Organization for
Research and Treatment of Cancer (EORTC) Core Quality-of-Life
Questionnaire, the QLQ-C30 (version 1), supplemented by a lung
cancer-specific questionnaire module, the QLQ-LC13. Both the
EORTC QLQ-C30 and the QLQ-LC13 have been thoroughly
pretested in large samples of lung cancer patients (Aaronson et al,
1993; Bergman et al, 1994), and they have demonstrated good
reliability and validity and sufficient ability to detect changes in
patients’ clinical status over time. In addition, two test items
hypothesized to measure aspects of peripheral neuropathy were
employed.
For all symptom measures and the majority of function
measures, response categories ranged from ‘not at all’, scored as 1,
to ‘very much’, scored as 4. The response categories for items
referring to physical and role function were dichotomous (yes or
no), while overall quality of life was scored on a semilinear scale,
ranging from 1 (very poor) to 7 (excellent). Scale scores were
calculated by dividing the sum of scores from individual items by
the number of items. For analysis and presentation, all scores (both
single item and scale scores) were linearly transformed to a 1–100
scale. For function scales and overall quality of life, 100 means
best possible reported function (i.e. complete absence of dysfunc-
tion), whereas for the remaining scales and items measuring
symptoms and side-effects 100 means worst possible reported
complaints.
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tionnaire at pretreatment, after 4, 8 and 16 weeks and, if treatment
was continued for further courses, after every second following
treatment course. In addition, quality-of-life assessment was
carried out at the time of treatment discontinuation.
Statistics
The relation between clinical variables and quality-of-life
measures was tested by factorial ANOVA or Spearman’s non-para-
metric correlation analysis. Change in quality-of-life measures
over time was analysed by repeated-measures ANOVA. A step-
wise multiple regression analysis was carried out to evaluate the
extent to which symptoms and side-effects influenced the variance
in overall quality-of-life ratings during treatment. In order to
reduce the random effects of multiple comparisons, the level of
statistical significance was set to P ≤ 0.01.
RESULTS
Patients and treatment duration
Between August 1992 and June 1994, 42 patients entered the
study, ten in Sweden and 32 in Denmark. Patient characteristics
are listed in Table 1. The median age was 56 years (range 37–70).
Two patients with stage III A disease were inoperable because of
mediastinal lymphadenopathy. Of the 42 patients entered into the
phase II study and evaluated for toxicity, only 40 were valuable for
response. One patient was excluded before the completion of one
treatment course because of early death due to pulmonary
embolism and one because of lack of evaluable disease.
The number of completed treatment courses are given in Table
2. The 42 patients received a total of 168 treatment courses
(one treatment course equals 4 weeks) of the gemcitabine and
vindesine combination. The median number of completed treat-
ment courses was 3 (range 0–19) and median treatment duration
was 14 weeks (range 2–29). Ten patients (23%) received six or
more treatments.
Toxicity
The haematological as well as the non-haematological toxicity as
indicated by laboratory measurement are depicted in Table 3.
WHO grade III–IV leucocytopenia was observed in five patients
(12%). Neutrophil counts were available in 33 patients, of whom
13 (39%) had grade IV neutropenia. There were no septic deaths.
Thrombocytopenia grade III–IV was observed in six patients
(15%) without any bleeding episodes.
The liver toxicity is outlined in Table 3. A transient rise in alka-
line phosphatase equal to WHO grade I–III toxicity occurred in 25
patients (60%) and a rise in alanine transaminase equal to WHO
grade I–III occurred in 33 patients (79%). One patient (2%) had an
increase in bilirubin equal to WHO grade IV toxicity but no other
grade IV liver toxicity was observed. The hepatic toxicity was
reversible in all cases.
With respect to renal toxicity, four patients (13%) exhibited a
decrease in glomerular filtration rate below normal limits as indi-
cated by chrom-EDTA clearance. This was reversible in three
patients, while one patient developed a non-reversible renal insuf-
ficiency. Two patients had an increase in creatinine level to WHO
grade I or III level (Table 3). Proteinuria was observed in 28
patients (67%) and haematuria in 24 patients (57%) (Table 4). The
mechanism for the renal toxicity is unknown.
A variety of non-laboratory toxicities were encountered, as
indicated in Table 4. The majority of patients (34, 81%) developed
peripheral neuropathy, with nine patients (21%) experiencing WHO
grade III neuropathy and none grade IV neuropathy (Table 4).
Ten patients (24%) complained of dyspnoea (Table 4). The venti-
lation capacity was measured by peak-flow measurements immedi-
ately before chemotherapy, immediately after chemotherapy and 1
and 2 h later. This procedure was initiated after nine patients had
been included in the study because one patient developed severe
dyspnoea causing hospitalization. A peak-flow reduction of more
than 50% within 2 h after drug infusion compared with preinfusion
level occurred in three patients (9%) and the dyspnoea caused
hospitalization in two patients but was uniformly reversible. In one
of these patients the dyspnoea disappeared spontaneously within
half an hour, whereas the other patient developed respiratory insuf-
ficiency with dyspnoea and cyanosis. On auscultation there was a
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Table 1 Patients characteristics (n = 42)
n %
Treatment centre
Rigshospitalet 14 (33%)
Herlev Hospital 18 (43%)
Renströmska Hospital 10 (24%)
Gender
Male 24 (57%)
Female 18 (43%)
Histology
Squamous cell 13 (31%)
Adenocarcinoma 22 (52%)
Large-cell carcinoma 7 (17%)
Tumour grade
Well differentiated 2 (5%)
Moderately differentiated 3 (7%)
Poorly differentiated 19 (45%)
Unknown 18 (43%)
Stage
III A 2 (5%)
III B 17 (40%)
IV 23 (55%)
Performance status (WHO)
0 4 (10%)
1 35 (83%)
2 3 (7%)
Table 2 Number of completed treatment courses (one cycle = 4 weeks)
No. courses No. patients %
0 1 2.4
1 5 11.9
2 6 14.3
3 11 26.2
4 7 16.7
5 2 4.8
6 4 9.5
7 3 7.1
8 2 4.8
19 1 2.4
Median three completed courses (range 0–19).prolonged expiration phase without crepitation and an arterial
puncture showed hypoxia and hypercapnia. ECG showed sinus
rhythm and chest radiography revealed no signs of new events.
Both acute myocardial infarction and pulmonary embolism were
ruled out. The patients were treated with inhalation of terbutaline
and intravenous administration of loop diuretics, terbutaline, theo-
phyllamine and glucocorticoids. The pulmonary symptoms were
completely reversible and the second patient was not re-exposed to
gemcitabine and vindesine.
The cumulated median administered doses of gemcitabine and
vindesine were 9000 mg m–2 (range 1000–48 750) and 21 mg m–2
(range 3–45) respectively. The cumulated dose intensity (planned
dose divided by actual administered dose) was 84% for gem-
citabine and 70% for vindesine. The reasons for dose reductions
are outlined in Table 5. The most frequent reasons for vindesine
dose reduction were paraesthesia (19 patients) and leucopenia
(nine patients).
Responses
The objective response rate for 40 assessable patients was 20%
(95% confidence limits 9–36%), with one complete response (2.5%)
and seven partial responses (17.5%). Stable disease was noted in 28
patients (70%) and four patients (10%) had disease progression. The
median response duration was 31 weeks (range 11–83 weeks).
The median overall survival time from start of treatment was 31
weeks (range 2–171 weeks), and the 1-and 2-year survival rates
were 33% and 7% respectively. All patients have since died.
Quality of Life
Forty-one patients were evaluable for quality of life at baseline
(pretreatment). Follow-up (on-treatment) assessments after 4, 8
and 12–16 weeks were completed by 33, 26 and 22 patients
respectively. Overall compliance in terms of completed/expected
questionnaires was 73%.
Function and global quality-of-life scores at baseline are
displayed in Table 6. For comparison, the baseline scores obtained
in a large international field study of the EORTC questionnaire
(Aaronson et al, 1993), comprising a comparable group of patients
with non-resectable lung cancer, are included in the table. At base-
line, women reported worse emotional function than did men
(emotional function score 58 in women vs. 76 in men, P = 0.001).
No other significant interaction effects of pretreatment objective
clinical variables on patient-rated function measures were
observed (Table 1).
Figure 1 displays the mean scores for physical, emotional and
social function and overall quality of life during the first four treat-
ment courses. Following the second treatment course, there was a
significant deterioration of the mean self-reported physical func-
tion (P < 0.0001). A similar trend towards deterioration was seen
in social function (P < 0.05). In contrast, the mean emotional
function score improved after one treatment course (P < 0.01),
although the mean overall quality-of-life score remained essen-
tially unchanged during treatment. The deterioration of physical
function during the first two treatment cycles was most
pronounced in patients who did not have an objective tumour
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Table 3 Worst haematological and non-haematological toxicity during gemcitabine and
vindesine treatment in 42 patients
WHO grades [no. of patients (%)]
Toxicity 0 1 2 3 4
Haematological
Leucocyte count 8 (19) 15 (36) 14 (33) 4 (10) 1 (2)
Neutrophil counta 9 (27) 7 (21) 4 (12) 10 (30) 3 (9)
Thrombocyte count 31 (74) 2 (5) 3 (7) 4 (10) 2 (5)
Haemoglobin 15 (36) 17 (41) 9 (21) 1 (2) 0
Non haematological
Alkaline phosphatase 17 (41) 16 (38) 7 (17) 2 (5) 0
Alanine transaminase 9 (21) 10 (24) 15 (36) 8 (19) 0
Bilirubin 39 (93) 2 (5) 0 0 1 (2)
Creatinine 40 (95) 1 (2) 0 1 (2) 0
aData on neutrophil counts available in 33 patients.
Table 4 Toxicity observed in 42 patients treated with gemcitabine and vindesine
WHO grades [no. of patients (%)]
Toxicity 0 1 2 3 4
Nausea/vomiting 10 (24) 12 (29) 19 (45) 1 (2) 0
Alopecia 23 (55) 4 (10) 10 (24) 5 (12) 0
Infection 32 (76) 6 (14) 4 (10) 0 0
Fever 27 (64) 7 (17) 8 (19) 0 0
Cutaneous (rash) 26 (62) 5 (12) 11 (26) 0 0
Pulmonary (dyspnoea) 32 (76) 6 (14) 1 (2) 2 (5) 1 (2)
Proteinuria 14 (33) 25 (60) 3 (7) 0 0
Haematuria 18 (43) 22 (52) 0 2 (5) 0
Diarrhoea 36 (86) 3 (7) 3 (7) 0 0
Constipation 24 (57) 13 (31) 2 (5) 3 (7) 0
Peripheral neuropathy 8 (19) 9 (21) 16 (38) 9 (21) 0response (P = 0.033 for interaction effect; two-factor repeated
measures ANOVA).
Mean symptom scores at baseline and changes to follow-up
assessments during treatment are displayed in Table 7. There was a
significant increase (i.e. deterioration) in the mean fatigue score
after two treatment courses (P < 0.0001), although the deteriora-
tion did not proceed in patients who received further treatment.
Increased levels of constipation were reported after the first treat-
ment course (P < 0.01). Patients’ ratings of hair loss and symptoms
related to peripheral neuropathy increased significantly during
treatment (P < 0.0001 at all follow-up assessments). The
remaining symptom score changes were non-significant.
The extent to which disease- and treatment-related symptoms
influenced the overall quality-of-life ratings during treatment was
evaluated by means of a stepwise regression analysis. The regres-
sion model included pain, fatigue, dyspnoea and appetite loss as
independent variables because the variables correlated with
quality of life in univariate analysis (data now shown). After 4
weeks, pain and fatigue entered the multivariate model,
explaining 66% of the variance of overall quality-of-life ratings
(multiple R = 0.814), whereas after 8 weeks only fatigue entered
the model.
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Table 5 Reasons for dose reductionsa (cumulated) among 42 evaluable
patients
No. of patients (%)
Gemcitabine Vindesine
Leucopenia 18 9
Thrombocytopenia 11 1
Paraesthesiae 19
Constipation 5
Oedema 3
Haematuria 1 2
Renal function 2
SGOT elevation 1
Rash 1
Dyspnoea 1
aIndividual patients may have more than one reason for dose reduction.
Table 6 Baseline (pretreatment) function and overall quality-of-life scores in
41 study patients. For comparison, reference baseline data on 305 patients
with non-resectable lung cancer and similar performance status (Aaronson et
al 1993) are included
Gemcitabin/vindesine data EORTC data
mean (s.d.) mean (s.e.)
Function scale
Physical 67.5 (24.3) 65.8 (1.6)
Role 59.5 (37.0) 57.3 (2.2)
Emotional 65.5 (22.5) 70.0 (1.3)
Cognitive 85.3 (20.5) 83.6 (1.2)
Social 82.2 (21.2) 77.3 (1.6)
Overall quality of life 55.2 (23.5) 56.7 (1.3)
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Figure 1 Changes in mean physical (A), emotional (B) and social function (C) and quality-of-life (D) scores during treatment with gemcitabin and vindesine. Score
range from 0 to 100, with 100 indicating the best possible rating (i.e. absence of reported dysfunction). Line charts are presented separately for patients measured
from start of treatment to week 4 (— —, n = 33), from start of treatment to week 8 (— —, n = 26) and from start of treatment to weeks 12–16 (– – –, n = 22)DISCUSSION
The goal of combination chemotherapy is to increase treatment
efficiency through the synergistic combination of drugs, thus
avoiding cross-toxicities. Usually, for an additive effect to be
exerted, the cytostatic agents have to possess different modes of
action on the neoplastic cells. Although the latter point is fulfilled
with the current combination of gemcitabine and vindesine, the
first point is not completely satisfied. Because of the partly over-
lapping toxicity, especially with respect to myelotoxicity, neither
of the two cytostatic agents applied could be used in the optimal
dose from the studies of single-agent doses. The response rate of
20% observed with gemcitabine and vindesine with the currently
applied doses was disappointing as it was of the same order as
achieved with either gemcitabine (Hansen et al, 1997) or vindesine
alone (Sørensen et al, 1993). However, with the present haemato-
logical toxicity data at hand, and with 39% of the patients having
neutropenia WHO grade III–IV (Table 3), it does not appear
feasible to increase further the dosage of the individual agents
used in this combination.
Renal toxicity was more pronounced than would be expected
based on the toxicity profile of both gemcitabine and vindesine. In
four patients (13%) the glomerular filtration rate was decreases
below normal limits as indicated by chrom-EDTA clearance; this
effect was totally reversible in three patients but progressed to
renal insufficiency in one patient. Also, the occurrence of protein-
uria in 28 patients (67%) and haematuria in 24 patients (57%) indi-
cates that this antineoplastic regimen can be attributed some renal
toxicity, the precise mechanism for which is as yet undetermined.
One might speculate whether it may be a result of pharmacokinetic
changes when these two drugs are given together. This point has,
however, not been investigated.
Also, the mechanism for the dyspnoea observed in some patients
remained unknown. However, based on the clinical appearance and
the responsiveness to bronchodilatating drugs points towards an
element of bronchoconstriction, though a minor pulmonary oedema
might also, theoretically, contribute to the condition.
The principal components of health-related quality of life may
be affected to various degrees, and in different directions, by
cancer and its treatment. Thus, a multidimensional approach to
quality-of-life assessment enhances the sensitivity in detecting
differentiated associations between disease or treatment and
subjective outcomes. This was clearly demonstrated in the present
study, in which patients with advanced NSCLC deteriorated with
regard to physical functioning and fatigue, but showed improved
emotional functioning, and retained their overall quality of life
during treatment. The pattern of changes is consistent with
previous findings in both small-cell and non-small-cell lung
cancer populations receiving chemotherapy (Kaasa et al, 1988;
Bergman et al, 1992; Aaronson et al, 1993), although the magni-
tude of changes sometimes diverged from what could be expected.
In particular, the increase in fatigue levels during treatment was
more pronounced than has been reported in clinical trials of some
other chemotherapy regimens with moderate activity in NSCLC,
e.g. carboplatin/etoposide (Helsing et al, 1998).
Tumour response is, to some extent, associated with changes in
subjective outcome measures during treatment for lung cancer,
and the lack of anti-tumour activity has been associated with a
deterioration of functional measures (Bergman et al, 1991; Kaasa
and Masthekaasa, 1998). In the present study, the mean physical
function value dropped earlier in non-responding patients than in
responders, supporting the hypothesis that objective tumour
response may contribute to a delay in the functional deterioration
that will eventually occur in a vast majority of patients with non-
resectable lung cancer.
When interpreting the variation in quality-of-life dimensions
during treatment, one has to consider the marginals for changes
from baseline measurements. Patient-rated quality of life and phys-
ical functioning, as measured with the EORTC questionnaire, have
been shown to vary significantly from observed-rated performance
status (Aaronson et al, 1993). In the present study, 91% of the
patients had a WHO performance status of 0 or 1 at baseline, indi-
cating that they had no major functional limitations prior to the onset
of treatment. Consequently, the marginals for functional improve-
ment during treatment were small, and the on-treatment quality-of-
life assessments were likely to capture principally adverse treatment
effects and symptoms due to disease progression. Taking this view, a
delay in deterioration of quality of life may be interpreted as a bene-
ficial effect of treatment on the patients’ well-being.
In order to improve further the activity for the new chemothera-
peutic agents with significant activity in NSCLC, they most likely
are to be combined with a platinum analogue, which has been the
focus of several investigations (Sørensen, 1994; Cojean et al, 1995;
Edelman et al, 1996). A review of vindesine in NSCLC covering
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Table 7 Baseline (pretreatment) symptom scores in 41 evaluable patients and mean score changes from
baseline during treatment. Positive score changes indicate increased symptoms (i.e. deterioration);
negative score changes indicate decreased symptoms (i.e. improvement)
Mean score (s.d.) Mean score changes from baseline
at baseline 4 weeks 8 weeks 12–16 weeks
(n = 41) (n = 34) (n = 27) (n = 22)
Pain 34.5 (30.9) 1.6 3.5 13.1
Fatigue 42.5 (23.6) 11.2 21.5 13.8
Dyspnoea 30.6 (23.6) 1.3 7.2 6.7
Sleep disturbance 27.3 (29.5) –4.6 –1.1 4.5
Appetite loss 36.5 (33.7) 5.1 10.0 9.4
Nausea/vomiting 15.5 (24.8) 2.2 –2.4 –5.5
Coughing 46.9 (29.7) –11.3 –12.5 –11.7
Haemoptysis 4.9 (14.0) 0 –3.8 –4.3
Constipation 10.5 (20.2) 18.8 13.6 8.7
Diarrhoea 7.1 (15.6) 3.1 5.0 –2.9
Peripheral neuropathy 7.6 (8.1) 28.3 49.4 53.0
Hair loss 0 38.4 54.4 46.3accumulated data from eight randomized studies, including a total
of 466 patients receiving vindesine + cisplatin, revealed 141
responding patients (30% response rate, 95% confidence limits
26–34%), with response rate in the individual studies ranging from
19% to 67% (Sørensen et al, 1993). Similarly, gemcitabine has been
evaluated in combination with cisplatin and in two dose escalation
studies involving a total of 22 patients, 13 responses were noted
with response rates in the individual studies ranging from 58%
(Sheperd et al, 1994) to 60% (Steward et al, 1994). Similarly, two
phase II studies using this combination observed responses in 26
out of 48 patients (54%, 95% confidence limits 39–69%; Crino et
al, 1997), and in 26 out of 50 evaluable patients (52%, 95% confi-
dence limits 37–66%; Abratt et al, 1997). Whether these promising
response rates will persist when more patients are treated with this
combination in randomized trials is awaited with interest, as is the
effect on survival and symptomatology score.
A dose-escalation study evaluating a combination of vinorel-
bine and gemcitabine revealed a preliminary response rate of 20%
(95% confidence limits 8–39%), but the maximal tolerated dose
was not reached (Krajnik et al, 1997) Further evaluation of the
active single agents in NSCLC in combination with a platinum
analogue with or without additional cytostatic agents included,
should have priority in order to further enhance our possibilities of
influencing the natural course of this grave disease.
With respect to quality of life, treatment with gemcitabine and
vindesine in non-resectable NSCLC did not significantly interfere
with patients’ emotional function or overall quality of life as
measured by the EORTC QLQ-C30, but it produced significant
levels of peripheral neurotoxic symptoms, and it may have
contributed to an increase in fatigue levels that was a significant
determinator of overall quality-of-life ratings during treatment. In
view of a modest objective tumour response rate, the subjective
treatment outcomes do not support gemcitabine and vindesine
used in the current schedule as a combination regimen of choice
for further comparative chemotherapy trials.
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